title: Reversible ventricular arrythmia induced by dasatinib.
abstract: Ventricular arrhythmias induced by dasatinib are rare events, but physicians in charge of chronic myeloid leukemia patients should be aware of such potential complications and the need for regular ECG controls during treatment with tyrosine kinase inhibitors.
authors.affiliation: Department of Internal Medicine, University of Geneva Hospitals Geneva, Switzerland.
authors.forename: Hervé
authors.initials: H
authors.lastname: Spechbach
authors.affiliation: Department of Internal Medicine, University of Geneva Hospitals Geneva, Switzerland.
authors.forename: Philippe
authors.initials: P
authors.lastname: Morel
authors.affiliation: Department of Clinical Pharmacology and Toxicology and Regional Pharmacovigilance Centre, University of Geneva Hospitals Geneva, Switzerland.
authors.forename: Kuntheavy
authors.initials: K
authors.lastname: Ing Lorenzini
authors.affiliation: Department of Clinical Pharmacology and Toxicology and Regional Pharmacovigilance Centre, University of Geneva Hospitals Geneva, Switzerland.
authors.forename: Marie
authors.initials: M
authors.lastname: Besson
authors.affiliation: Prison Medicine Unit Department of Community Medicine, University of Geneva Hospitals Geneva, Switzerland.
authors.forename: Laurent
authors.initials: L
authors.lastname: Gétaz
authors.affiliation: Department of Cardiology, University of Geneva Hospitals Geneva, Switzerland.
authors.forename: Henri
authors.initials: H
authors.lastname: Sunthorn
authors.affiliation: Department of Haematology, University of Geneva Hospitals Geneva, Switzerland.
authors.forename: Yves
authors.initials: Y
authors.lastname: Chalandon
keywords: Adverse drug reaction; BCR-ABL (breakpoint cluster region-abelson); chronic myeloid leukaemia; dasatinib; ventricular arrhythmia